Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Cash from Financing Activities (2016 - 2025)

Apyx Medical's Cash from Financing Activities history spans 15 years, with the latest figure at $9.5 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 40.31% year-over-year to $9.5 million; the TTM value through Dec 2025 reached $9.6 million, up 42.03%, while the annual FY2025 figure was $9.6 million, 42.03% up from the prior year.
  • Cash from Financing Activities reached $9.5 million in Q4 2025 per APYX's latest filing, up from $45000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $23.8 million in Q4 2023 to a low of -$61000.0 in Q1 2021.
  • Average Cash from Financing Activities over 5 years is $2.4 million, with a median of $35000.0 recorded in 2025.
  • Peak YoY movement for Cash from Financing Activities: plummeted 506.67% in 2021, then skyrocketed 238540.0% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$39000.0 in 2021, then surged by 74.36% to -$10000.0 in 2022, then surged by 238540.0% to $23.8 million in 2023, then crashed by 71.65% to $6.8 million in 2024, then surged by 40.31% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Cash from Financing Activities are $9.5 million (Q4 2025), $45000.0 (Q3 2025), and $25000.0 (Q2 2025).